Saturday 17 October 2026
Export TARS’s income statement to Excel — free account
Tarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024. In the quarter to June 2026, revenue grew 69.4%, EPS grew 10.4%, free cash flow grew 288.1% and total debt was flat, each against the same quarter a year earlier.
68.07
2.92
−4.11%
Follow TARS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
6.92 | 7.58 | 5.63 | 4.50 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 58.11 | |
P/Operating CF |
138.70 | 176.99 | (122.24) | 44.61 | |
P/B ratio |
7.56 | 9.96 | 8.64 | 7.88 | |
Price to Tangible BV |
7.73 | 10.18 | 8.82 | 8.04 | |
EV/Sales |
6.02 | 6.81 | 5.04 | 3.88 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(40.82) | (247.04) | (163.95) | 31.75 | |
EV/FCF |
(33.10) | (98.24) | (66.54) | 50.09 | |
Quick Ratio |
4.07 | 3.72 | 3.53 | 3.12 | |
Current Ratio |
4.29 | 3.85 | 3.74 | 3.20 | |
Net Debt/EBITDA |
21.33 | 41.60 | 49.59 | 19.33 | |
Debt/Assets |
13.52% | 12.89% | 12.49% | 11.91% | |
Debt/Equity |
0.22 | 0.21 | 0.21 | 0.21 | |
Asset Turnover |
0.80 | 0.96 | 0.99 | 1.10 | |
Operating CF/Net income |
(1.45) | (2.31) | 3.54 | (3.30) | |
Capex/Depreciation |
2.07 | 19.50 | 23.00 | (10.07) | |
Interest Coverage |
(6.41) | (3.60) | (2.88) | (9.23) | |
Research and Development Expense of Revenue |
13.72% | 11.89% | 13.79% | 17.83% | |
Selling, General and Administrative Expense of Revenue |
91.52% | 86.16% | 84.19% | 86.65% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
10.31% | 9.44% | 7.38% | 7.64% | |
Graham Net Nets |
0.12 | 0.09 | 0.10 | 0.11 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(3.40%) | (1.98%) | (1.63%) | (1.73%) | |
Free Cash Flow Yield |
(2.63%) | (0.92%) | (1.35%) | 1.72% | |
Revenue per Share |
2.79 | 3.63 | 3.77 | 4.01 | |
Operating CF per Share |
0.43 | 0.46 | (0.57) | 1.41 | |
Capex per Share |
(0.04) | (0.15) | (0.14) | (0.09) | |
Free Cash Flow per Share |
0.38 | 0.31 | (0.71) | 1.32 | |
Cash per Share |
9.43 | 10.00 | 9.05 | 10.36 | |
Shareholders Equity per Share |
7.86 | 8.22 | 8.12 | 7.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.86 | 8.22 | 8.12 | 7.99 | |
Free Cash Flow |
16.35 | 12.97 | (30.47) | 57.15 | |
Working Capital |
384.65 | 387.09 | 393.72 | 386.24 | |
Capital Expenditures |
(1.91) | (6.36) | (5.82) | (4.07) | |
Net Current Asset Value |
302.23 | 304.05 | 305.05 | 297.58 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.04 | 0.04 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
52.32 | 67.58 | 90.68 | 79.27 | |
Average Payables |
79.02 | 12.90 | 50.25 | 59.39 | |
Average Inventory |
3.34 | 3.50 | 3.64 | 4.13 | |
Average Assets |
455.43 | 469.57 | 540.94 | 553.07 | |
Average Common Equity |
286.28 | 283.98 | 345.70 | 339.67 |
Columns are period end dates